Study of a new drug plus an antibody drug for HER2-low breast cancer
Part of Cancer, Skin clinical trials.
This study tests a new treatment combining two drugs (SSGJ-612 and an antibody-drug) for people with a certain type of advanced breast cancer (hormone receptor-positive and HER2-low or ultra-low). The goal is to see if this combination can help when endocrine therapy has stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have metastatic (spread) breast cancer that is hormone receptor-positive and HER2-low or ultra-low.
- Your cancer has gotten worse after at least 2 lines of endocrine therapy, or within 6 months of starting first-line treatment with a CDK4/6 inhibitor and endocrine therapy.
- You either have had one line of chemotherapy for metastatic cancer (for part 1) or no chemotherapy for metastatic cancer (for part 2).
- You have at least one measurable tumor that can be evaluated for response.
- You have a life expectancy of at least 3 months and are willing to follow the study procedures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how well and how safely different combinations of cancer drugs work for people with metastatic or inoperable locally advanced breast cancer. It may help by finding a better treatment option and collecting information to guide future care.
This trial tests a combination of targeted therapies (trastuzumab and pertuzumab) with chemotherapy (docetaxel) and an experimental drug (QL1706) given before surgery to shrink early or locally advanced HER2-positive breast cancer. It aims to see if this approach improves outcomes before definitive surgery.
This study tests a new treatment for advanced HER2-negative breast cancer. Doctors will take immune cells from lymph nodes near your tumor, grow them in a lab, and then give them back to you along with chemotherapy and immunotherapy. This approach aims to help your body fight the cancer more effectively.
This trial tests two new antibody drugs (SSGJ-705 and SSGJ-612), alone or combined with chemotherapy, in patients with advanced cancers that have a protein called HER2. The study aims to see if this combination can shrink tumors and help patients live longer.
This trial tests a new drug called SSGJ-612 for people with advanced solid tumors that have stopped responding to standard treatments. It is specifically for patients whose tumors have a protein called HER2, and it aims to see if the drug can shrink or control the cancer.
This trial tests a new drug called SSGJ-705, given alone or with other treatments, for advanced cancers that have a specific protein (HER2) on their surface. It is for people with lung, breast, or stomach cancer that has spread and hasn't gotten better with other treatments.
Hear when a new Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.